The estimated Net Worth of Kevin G Lafond is at least $1.49 Million dollars as of 8 January 2021. Mr. Lafond owns over 18,020 units of Alaunos Therapeutics Inc stock worth over $55,650 and over the last 11 years he sold ZIOP stock worth over $708,700. In addition, he makes $725,214 as Senior Vice President - Finance, Chief Accounting Officer, and Treasurer at Alaunos Therapeutics Inc.
Sign up
Mr. Lafond ZIOP stock SEC Form 4 insiders trading
Kevin has made over 4 trades of the Alaunos Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 18,020 units of ZIOP stock worth $55,682 on 8 January 2021.
The largest trade he's ever made was selling 57,500 units of Alaunos Therapeutics Inc stock on 3 June 2015 worth over $554,875. On average, Kevin trades about 7,768 units every 146 days since 2013. As of 8 January 2021 he still owns at least 63,965 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Mr. Lafond stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Lafond biography
Kevin G. Lafond CPA serves as Senior Vice President - Finance, Chief Accounting Officer, Treasurer of the Company. Mr. Lafond has served as our Sr. Vice President Finance, Chief Accounting Officer and Treasurer since June 2013 and is our principal accounting officer. Previously, Mr. Lafond served as our Corporate Controller since he joined us in February 2009 until June 2013. Prior to joining us, Mr. Lafond served as Controller of Helicos Biosciences Corporation, a public life sciences equipment manufacturer, from February 2007 to October 2008. Mr. Lafond holds a bachelor’s degree from Plymouth State University, master’s degrees in both accounting and taxation from Bentley University and is a Certified Public Accountant.
What is the salary of Kevin Lafond?
As the Senior Vice President - Finance, Chief Accounting Officer, and Treasurer of Alaunos Therapeutics Inc, the total compensation of Kevin Lafond at Alaunos Therapeutics Inc is $725,214. There are 3 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of $3,317,570.
How old is Kevin Lafond?
Kevin Lafond is 64, he's been the Senior Vice President - Finance, Chief Accounting Officer, and Treasurer of Alaunos Therapeutics Inc since 2019. There are 1 older and 16 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
What's Kevin Lafond's mailing address?
Kevin's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON, MA, 02129.
Insiders trading at Alaunos Therapeutics Inc
Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk, and Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
What does Alaunos Therapeutics Inc do?
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
What does Alaunos Therapeutics Inc's logo look like?
Complete history of Mr. Lafond stock trades at Alaunos Therapeutics Inc
Alaunos Therapeutics Inc executives and stock owners
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Laurence Cooper,
Chief Executive Officer, Director -
Satyavrat Shukla,
Chief Financial Officer -
Robert Hadfield,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary -
Kevin Lafond,
Senior Vice President - Finance, Chief Accounting Officer, Treasurer -
Heidi Hagen,
Independent Director -
Dr. Eleanor de Groot Ph.D.,
Exec. VP of Operations -
Christopher Bowden,
Independent Director -
Scott Tarriff,
Independent Chairman of the Board -
Dr. Raffaele Baffa M.D., Ph.D.,
Chief Medical Officer and Exec. VP of R&D -
Elan Ezickson,
Independent Director -
Zuie-Chin Huang M.B.A.,
Exec. Chairman -
Mary Thistle,
Independent Director -
Raffaele Baffa,
Chief Medical Officer -
Christopher Taylor,
Vice President, Investor Relations and Corporate Communications -
James Huang,
Director -
J. Kevin Buchi,
Director -
Lynn Ferrucci,
Executive Vice President of Human Resources, Facilities, Administration and IT -
Eleanor De Groot,
Executive Vice President, General Manager, Cell Therapy -
Jill Buck,
Executive Vice President, General Manager, Gene Therapy -
Dr. Drew Deniger,
Head of TCR-T Cell Therapy Program -
Dr. David M. Mauney M.D.,
Consultant -
Melinda Lackey,
Sr. VP of Legal -
Michael Wong,
VP of Fin. & Principal Accounting Officer -
Timothy M. Cunningham CPA, M.B.A.,
Interim CFO & Principal Financial Officer -
Kevin S. Boyle Sr.,
CEO & Director -
James Anthony Cannon,
Director -
Randal Jintrexon Corp Kirk,
-
Murray Brennan,
Director -
Wyche Fowler,
Director -
Randal J Kirk,
Director -
Caesar J Belbel,
COO, CLO, and Secretary -
Michael Weiser,
Director -
Francois Lebel,
Executive Vice President R&D -
David M Md Mauney,
President -
Douglas W. Pagan,
Director -
Scott Braunstein,
Director -
Hagop Youssoufian,
Executive VP, CMO -
Timothy Mcinerney,
Director -
Jonathan Lewis,
CEO -
Jason Amello,
Executive Vice President & CFO -
Richard E Bagley,
President, COO & Treasurer -
George B Abercrombie,
Director -
Robert Peter Gale,
Senior V.P. of Research -
Lindsay A Md Rosenwald,
10% owner -
Woodlands Health Ventures F...,
10% owner -
Gary S Fragin,
Director -
Sath Shukla,
EVP, Chief Financial Officer -
Jaime Vieser,
Director -
Holger Weis,
Director -
Robert W Postma,
Director -
Kevin S. Sr. Boyle,
Chief Executive Officer -
Melinda Lackey,
Senior Vice President, Legal